<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Unified all-atom molecule generation with neural fields - Health AI Hub</title>
    <meta name="description" content="This paper introduces FuncBind, a novel framework leveraging neural fields and score-based generative models adapted from computer vision, to unify all-atom mol">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>Unified all-atom molecule generation with neural fields</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2511.15906v1" target="_blank">2511.15906v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-11-19
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Matthieu Kirchmeyer, Pedro O. Pinheiro, Emma Willett, Karolis Martinkus, Joseph Kleinhenz, Emily K. Makowski, Andrew M. Watkins, Vladimir Gligorijevic, Richard Bonneau, Saeed Saremi
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.LG, q-bio.BM
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 0.95 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2511.15906v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2511.15906v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper introduces FuncBind, a novel framework leveraging neural fields and score-based generative models adapted from computer vision, to unify all-atom molecule generation across diverse atomic systems. FuncBind overcomes modality-specific limitations, enabling a single model to generate small molecules, macrocyclic peptides, and antibody complementarity-determining region loops conditioned on target structures, and demonstrated successful *in vitro* generation of novel antibody binders.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This framework significantly advances structure-based drug discovery by enabling the de novo design of diverse therapeutic molecules, including small molecule drugs, peptides, and antibodies, within a unified and efficient platform. Its ability to generate novel antibody binders *in vitro* directly supports the accelerated development of new biotherapeutics and diagnostic agents.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The AI application is the use of neural fields and score-based generative models to design and discover novel therapeutic molecules (small molecules, peptides, and antibodies) for various diseases. This accelerates the drug discovery process by computationally generating candidate molecules with desired properties, potentially leading to new drugs and treatments.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>FuncBind addresses the challenge of modality-specific generative models in structure-based drug design by proposing a unified, all-atom framework.</li>
                    
                    <li>It utilizes neural fields to represent molecules as continuous atomic densities, making the representation modality-agnostic and capable of handling diverse molecular types and sizes.</li>
                    
                    <li>The generative process is powered by score-based models, employing modern neural network architectures adapted from computer vision literature.</li>
                    
                    <li>The model demonstrates competitive *in silico* performance across various molecular modalities, including small molecules, macrocyclic peptides, and antibody CDR loops, all conditioned on target structures.</li>
                    
                    <li>A key finding is the successful *in vitro* generation of novel antibody binders through de novo redesign of the CDR H3 loop from two chosen co-crystal structures.</li>
                    
                    <li>FuncBind is capable of handling variable atom/residue counts and non-canonical amino acids within its unified framework.</li>
                    
                    <li>The paper also contributes a new dataset and benchmark specifically for structure-conditioned macrocyclic peptide generation.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>FuncBind represents molecules as continuous atomic densities using neural fields, moving away from discrete molecular representations. It employs score-based generative models with advanced neural network architectures, adapted from computer vision, to learn and sample from the conditional distribution of molecular structures given a target. This unified approach allows the model to be trained on, and generate, diverse atomic systems ranging from small molecules to complex proteins like antibodies and peptides.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>['FuncBind achieved competitive *in silico* performance in generating target-conditioned small molecules, macrocyclic peptides, and antibody complementarity-determining region (CDR) loops.', 'The framework successfully generated *in vitro* novel antibody binders through de novo redesign of the CDR H3 loop, providing experimental validation of its capabilities.', 'Its modality-agnostic nature allows a single model to effectively handle diverse molecular systems, including those with variable atom/residue counts and non-canonical amino acids.', 'A new dataset and benchmark were introduced to facilitate further research in structure-conditioned macrocyclic peptide generation.']</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>FuncBind has the potential to revolutionize preclinical drug discovery by streamlining and accelerating the design of novel therapeutics. Its unified approach could reduce the time and cost associated with identifying drug candidates across various modalities (small molecules, peptides, antibodies), directly impacting the development of new treatments for cancer, autoimmune disorders, infectious diseases, and other conditions requiring targeted molecular interventions.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The abstract does not explicitly state limitations of the FuncBind framework. It highlights competitive *in silico* performance, implying potential areas for further improvement or specific niches where specialized models might still excel, but no direct caveats are provided.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>While not explicitly stated as future directions, the introduction of a new dataset and benchmark for macrocyclic peptide generation implies a call for further research and development in this specific area, leveraging the capabilities of frameworks like FuncBind.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Drug Discovery</span>
                    
                    <span class="tag">Biologics Development</span>
                    
                    <span class="tag">Therapeutic Design</span>
                    
                    <span class="tag">Immunology</span>
                    
                    <span class="tag">Oncology</span>
                    
                    <span class="tag">Infectious Diseases</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Generative AI</span>
                    
                    <span class="tag tag-keyword">Drug Discovery</span>
                    
                    <span class="tag tag-keyword">Neural Fields</span>
                    
                    <span class="tag tag-keyword">Antibody Engineering</span>
                    
                    <span class="tag tag-keyword">Peptide Design</span>
                    
                    <span class="tag tag-keyword">Structure-Based Drug Design</span>
                    
                    <span class="tag tag-keyword">Molecular Generation</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Generative models for structure-based drug design are often limited to a specific modality, restricting their broader applicability. To address this challenge, we introduce FuncBind, a framework based on computer vision to generate target-conditioned, all-atom molecules across atomic systems. FuncBind uses neural fields to represent molecules as continuous atomic densities and employs score-based generative models with modern architectures adapted from the computer vision literature. This modality-agnostic representation allows a single unified model to be trained on diverse atomic systems, from small to large molecules, and handle variable atom/residue counts, including non-canonical amino acids. FuncBind achieves competitive in silico performance in generating small molecules, macrocyclic peptides, and antibody complementarity-determining region loops, conditioned on target structures. FuncBind also generated in vitro novel antibody binders via de novo redesign of the complementarity-determining region H3 loop of two chosen co-crystal structures. As a final contribution, we introduce a new dataset and benchmark for structure-conditioned macrocyclic peptide generation. The code is available at https://github.com/prescient-design/funcbind.</p>
            </section>

            
            <section class="paper-section">
                <h2>Comments</h2>
                <p>NeurIPS 2025</p>
            </section>
            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>